Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020010196 - COMPOSITIONS PHARMACEUTIQUES COMPRENANT DU MÉLOXICAM

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1. A method of treating migraine, comprising administering a dosage form comprising meloxicam, at least 400 mg of a bicarbonate, and a rizatriptan to a human being suffering from migraine; wherein the Tmax of rizatriptan in the dosage form is shorter than that in a reference dosage form comprising a) same amount of rizatriptan; 2) no meloxicam; and c) no bicarbonate.

2. The method of claim 1, wherein about 8 mg to about 13 mg of the rizatriptan is present in the dosage form based upon the weight of the rizatriptan in the free base form.

3. The method of claim 2, wherein the rizatriptan is present in a salt form in an amount that is a molar equivalent of about 10 mg of the rizatriptan in the free base form.

4. The method of claim 3, wherein the rizatriptan is present as rizatriptan benzoate.

5. The method of claim 1, wherein the dosage form contains about 15 mg to about 25 mg of meloxicam.

6. The method of claim 5, wherein the dosage form contains about 20 mg of meloxicam.

7. The method of claim 1, wherein the dosage form further comprises a cyclodextrin. 8. The method of claim 7, wherein the dosage form contains about 100 mg to about 175 mg of the cyclodextrin.

9. The method of claim 7, wherein the dosage form contains about 100 mg to about 140 mg of the cyclodextrin.

10. The method of claim 1, wherein the bicarbonate comprises sodium bicarbonate.

11. The method of claim 1, wherein the dosage form contains about 400 mg to about 600 mg of the bicarbonate.

12. The method of claim 1, wherein the dosage form contains about 500 mg of sodium bicarbonate.

13. The method of claim 1, wherein the dosage form contains about 50% to about 90% of the bicarbonate by weight.

14. The method of claim 1, wherein the dosage form has the property that 15 minutes after the dosage form is added to a simulated gastric fluid, the amount of the meloxicam dissolved in the simulated gastric fluid of the human being is greater than the amount of the meloxicam that is dissolved in the simulated gastric fluid of the human being as a result of adding a reference dosage form to the simulated gastric fluid, wherein the reference dosage form contains: 1) the same amount of meloxicam, and 2) no bicarbonate.

15. The method of claim 1, wherein the dosage form has the property that 15 minutes after the dosage form is added to a simulated gastric fluid, the amount of the rizatriptan dissolved in the simulated gastric fluid is greater than the amount of the meloxicam.

16. The method of claim 1, wherein the human being experiences pain relief sooner than would be experienced as a result of orally administering a reference dosage form containing: 1) the same amount of meloxicam, and 2) no bicarbonate.

17. The method of claim 1, wherein the dosage form has the property that 30 minutes after the dosage form is added to a simulated gastric fluid, at least about 50% of the rizatriptan in the dosage form is dissolved in the simulated gastric fluid.

18. The method of claim 1, wherein the dosage form has the property that 30 minutes after the dosage form is added to a simulated gastric fluid, at least about 50% of the meloxicam in the dosage form is dissolved in the simulated gastric fluid.

19. The method of claim 1, wherein the Tmax of meloxicam in the dosage form is less than about 1 hours.

20. The method of claim 1, wherein the Tmax of rizatriptan in the dosage form is less than about 2 hours.